Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance Licenses HAP Tech to Novo Nordisk

NEW YORK, Dec. 18 (Genome Web News) - Genaissance Pharmaceuticals has licensed its HAP technology to Novo Nordisk, which will use it in a drug-development program, the companies said today.


Terms of the agreement call for Novo Nordisk to pay Genaissance license and service fees, including fees for genotyping clinical samples. In exchange, Genaissance will have certain rights to develop and commercialize certain diagnostic products and services.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.